MARKET

IMRA

IMRA

Imara Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.19
-1.39
-4.86%
Opening 11:15 07/02 EDT
OPEN
28.87
PREV CLOSE
28.58
HIGH
29.29
LOW
26.50
VOLUME
24.17K
TURNOVER
--
52 WEEK HIGH
62.71
52 WEEK LOW
13.40
MARKET CAP
469.86M
P/E (TTM)
-4.9641
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMRA stock price target is 44.33 with a high estimate of 64.00 and a low estimate of 34.00.

EPS

IMRA News

More
Citigroup Downgrades Imara to Neutral, Raises Price Target to $34
Citigroup downgrades Imara (NASDAQ:IMRA) from Buy to Neutral and raises the price target from $30 to $34.
Benzinga · 2d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 2d ago
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
GlobeNewswire · 2d ago
Imara Added To Membership Of US Small-Cap Russell 2000 Index
Benzinga · 2d ago
Biotech IPOs are booming -- but it's not all about Covid-19
CNN.com · 06/25 12:43
Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
GlobeNewswire · 06/25 12:00
Imara Receives Orphan Drug Designation For IMR-687 For Treatment Of Beta-thalassemia
BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare
Benzinga · 06/24 11:09
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the U.S. Food and Drug Administra
GlobeNewswire · 06/24 11:00

Industry

Biotechnology & Medical Research
+0.86%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Symbol
Price
%Change

About IMRA

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.
More

Webull offers kinds of Imara Inc stock information, including NASDAQ:IMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRA stock methods without spending real money on the virtual paper trading platform.